AR056862A1 - 1,2-etilendiaminas sustituidas, medicamentos que contienen a estos compuestos, su uso y procedimiento para su preparacion - Google Patents
1,2-etilendiaminas sustituidas, medicamentos que contienen a estos compuestos, su uso y procedimiento para su preparacionInfo
- Publication number
- AR056862A1 AR056862A1 ARP060101206A ARP060101206A AR056862A1 AR 056862 A1 AR056862 A1 AR 056862A1 AR P060101206 A ARP060101206 A AR P060101206A AR P060101206 A ARP060101206 A AR P060101206A AR 056862 A1 AR056862 A1 AR 056862A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkynyl
- aryl
- cycloalkyl
- heterocyclyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- -1 iodine, hydroxy- Chemical class 0.000 abstract 55
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 17
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 17
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 12
- 229910052731 fluorine Inorganic materials 0.000 abstract 12
- 239000011737 fluorine Substances 0.000 abstract 12
- 125000001072 heteroaryl group Chemical group 0.000 abstract 12
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 11
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 11
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 11
- 229910052794 bromium Inorganic materials 0.000 abstract 11
- 229910052801 chlorine Inorganic materials 0.000 abstract 11
- 239000000460 chlorine Substances 0.000 abstract 11
- 125000000217 alkyl group Chemical group 0.000 abstract 9
- 125000000623 heterocyclic group Chemical group 0.000 abstract 9
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 8
- 125000003118 aryl group Chemical group 0.000 abstract 8
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 7
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 6
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 5
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 2
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 1
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 abstract 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical class NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 abstract 1
- 125000005018 aryl alkenyl group Chemical group 0.000 abstract 1
- 125000005418 aryl aryl group Chemical group 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05006939 | 2005-03-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR056862A1 true AR056862A1 (es) | 2007-10-31 |
Family
ID=36545049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060101206A AR056862A1 (es) | 2005-03-30 | 2006-03-29 | 1,2-etilendiaminas sustituidas, medicamentos que contienen a estos compuestos, su uso y procedimiento para su preparacion |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US7713961B2 (enExample) |
| EP (1) | EP1866034A1 (enExample) |
| JP (1) | JP2008534541A (enExample) |
| AR (1) | AR056862A1 (enExample) |
| CA (1) | CA2603404A1 (enExample) |
| TW (1) | TW200716152A (enExample) |
| WO (1) | WO2006103038A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2603404A1 (en) * | 2005-03-30 | 2006-10-05 | Boehringer Ingelheim International Gmbh | Substituted 1,2-ethylendiamines, medicaments comprising said compound; their use and their method of manufacture |
| JP2009503027A (ja) * | 2005-08-03 | 2009-01-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | アルツハイマー病ｉｉの治療のための置換エタン−１，２−ジアミン |
| EP1919861A2 (de) * | 2005-08-11 | 2008-05-14 | Boehringer Ingelheim International GmbH | Verbindungen zur behandlung der alzheimer erkrankung |
| US20090042867A1 (en) * | 2005-08-11 | 2009-02-12 | Klaus Fuchs | Compounds for the treatment of alzheimer's disease |
| EP1915339A1 (de) * | 2005-08-11 | 2008-04-30 | Boehringer Ingelheim International GmbH | Inhibitoren der beta-sekretase zur behandlung der alzheimer- erkrankung |
| CA2618474A1 (en) * | 2005-08-11 | 2007-02-15 | Boehringer Ingelheim International Gmbh | Compounds for treating alzheimer's disease |
| JP2012505241A (ja) | 2008-10-10 | 2012-03-01 | パーデュー・リサーチ・ファウンデーション | アルツハイマー病の治療用組成物 |
| EP2376083A4 (en) | 2008-11-20 | 2012-06-20 | Purdue Research Foundation | QUINAZOLIN-BASED BACE-1 INHIBITORS AND METHODS OF USE |
| WO2010065861A2 (en) * | 2008-12-05 | 2010-06-10 | Purdue Research Foundation | Inhibitors of bace 1 and methods for treating alzheimer's disease |
| JP2013506713A (ja) * | 2009-10-05 | 2013-02-28 | コメンティス，インコーポレーテッド | β−セクレターゼ活性を阻害するスルホンアミドピロリジン化合物及びその使用方法 |
| US20140066488A1 (en) * | 2012-08-30 | 2014-03-06 | Purdue Research Foundation | Inhibitors of Memapsin 2 Cleavage for the Treatment of Alzheimer's Disease |
| US20240383852A1 (en) * | 2021-03-12 | 2024-11-21 | Infex Therapeutics Limited | Anti-viral compounds |
| MX2023014754A (es) | 2021-06-18 | 2024-02-12 | Aligos Therapeutics Inc | Métodos y composiciones dirigidos a pd-l1. |
| CN119212987A (zh) | 2021-12-16 | 2024-12-27 | 安力高医药股份有限公司 | 用于靶向pd-l1的方法和组合物 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ184194A3 (en) | 1993-08-09 | 1995-03-15 | Lilly Co Eli | Aspartylprotease inhibitor and method of identifying thereof |
| US7087399B1 (en) | 1999-05-13 | 2006-08-08 | Scios, Inc. | β-secretase and modulation of β-secretase activity |
| EP1194449B1 (en) | 1999-06-28 | 2010-09-22 | Oklahoma Medical Research Foundation | Inhibitors of memapsin 2 and use thereof |
| CA2449948A1 (en) * | 2001-06-08 | 2002-12-19 | Elan Pharmaceuticals, Inc. | Methods of treating alzheimer's disease |
| EP1453516A2 (de) | 2001-10-17 | 2004-09-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren |
| AU2003206413A1 (en) * | 2002-01-04 | 2003-07-24 | Elan Pharmaceuticals, Inc. | Substituted amino carboxamides for the treatment of alzheimer's disease |
| US7763646B2 (en) * | 2002-09-27 | 2010-07-27 | Elan Pharmaceuticals, Inc. | Compounds for the treatment of alzheimer's disease |
| DE60329316D1 (de) * | 2002-11-12 | 2009-10-29 | Merck & Co Inc | Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer |
| US20050090449A1 (en) | 2003-05-13 | 2005-04-28 | Boehringer Ingelheim International Gmbh | Novel statine derivatives for the treatment of Alzheimer's disease |
| JP2007516207A (ja) * | 2003-06-30 | 2007-06-21 | メルク エンド カムパニー インコーポレーテッド | アルツハイマー病の治療のためのＮ−アルキルフェニルカルボキサミドβ−セクレターゼ阻害剤 |
| EP1750719A2 (en) | 2004-05-19 | 2007-02-14 | Boehringer Ingelheim International GmbH | Treatment of diseases associated with altered level of amyloid beta peptides |
| WO2005113582A1 (en) | 2004-05-22 | 2005-12-01 | Boehringer Ingelheim International Gmbh | Substituted ethane-1,2-diamines for the treatment of alzheimer's disease |
| WO2006050861A2 (en) | 2004-11-10 | 2006-05-18 | Boehringer Ingelheim International Gmbh | Statine derivatives for the treatment of alzheimer's disease |
| WO2006050862A1 (en) | 2004-11-10 | 2006-05-18 | Boehringer Ingelheim International Gmbh | Statine derivatives for the treatment of alzheimer's disease |
| CA2603404A1 (en) * | 2005-03-30 | 2006-10-05 | Boehringer Ingelheim International Gmbh | Substituted 1,2-ethylendiamines, medicaments comprising said compound; their use and their method of manufacture |
| JP2009503027A (ja) | 2005-08-03 | 2009-01-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | アルツハイマー病ｉｉの治療のための置換エタン−１，２−ジアミン |
| US20090042867A1 (en) | 2005-08-11 | 2009-02-12 | Klaus Fuchs | Compounds for the treatment of alzheimer's disease |
-
2006
- 2006-03-27 CA CA002603404A patent/CA2603404A1/en not_active Abandoned
- 2006-03-27 EP EP06723747A patent/EP1866034A1/en not_active Withdrawn
- 2006-03-27 JP JP2008503415A patent/JP2008534541A/ja active Pending
- 2006-03-27 WO PCT/EP2006/002769 patent/WO2006103038A1/en not_active Ceased
- 2006-03-29 TW TW095110860A patent/TW200716152A/zh unknown
- 2006-03-29 AR ARP060101206A patent/AR056862A1/es not_active Application Discontinuation
- 2006-03-30 US US11/278,059 patent/US7713961B2/en active Active
-
2009
- 2009-07-29 US US12/511,474 patent/US20090325940A1/en not_active Abandoned
-
2010
- 2010-04-13 US US12/759,167 patent/US20100204160A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1866034A1 (en) | 2007-12-19 |
| US7713961B2 (en) | 2010-05-11 |
| US20060223759A1 (en) | 2006-10-05 |
| WO2006103038A1 (en) | 2006-10-05 |
| CA2603404A1 (en) | 2006-10-05 |
| US20090325940A1 (en) | 2009-12-31 |
| US20100204160A1 (en) | 2010-08-12 |
| TW200716152A (en) | 2007-05-01 |
| JP2008534541A (ja) | 2008-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY33961A (es) | Compuestos de bis(fuoroalquil)-1,4-benziodiazepinona | |
| ECSP045476A (es) | Tiazolidinonas, su preparación y su uso como medicamentos | |
| UY32978A (es) | Derivados de la cromenona | |
| PE20160548A1 (es) | Sulfonamidas como moduladores de canales de sodio | |
| CO6561821A2 (es) | Compuesto n-(1h-indazol-4-il)imidazol[1.2-a]piridin -3-carboxamida sustituidos como inhibidores de cfms | |
| ECSP10010209A (es) | Agonistas novedosos de los receptores de glucocorticoides | |
| AR067107A1 (es) | Derivados de tiazol[5,4-b]piridin moduladores de sirtuinas | |
| EA201171098A1 (ru) | 8-замещенные хинолины и родственные аналоги в качестве модуляторов сиртуина | |
| AR063015A1 (es) | Derivados de quinazolinona 5-sustituida y composiciones que los comprenden y metodos para utilizarlos en el tratamiento del cancer | |
| UY27872A1 (es) | Inhibidores de caspasa y usos de los mismos. | |
| PA8604201A1 (es) | Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades | |
| BRPI0515546A (pt) | compostos para inflamação e usos imune-relacionados | |
| AR023971A1 (es) | Derivados de 4,5,6,7-tetrahidroindazol, procedimiento para la preparacion de los mismos y su utilizacion como agentes antitumorales | |
| AR090712A1 (es) | Agentes para tratar trastornos que implican la modulacion de receptores de rianodina | |
| UY28150A1 (es) | Agentes terapeuticos | |
| CO6321241A2 (es) | Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp) | |
| AR056560A1 (es) | Pirrolopiridinonas como moduladores cb1 | |
| AR051326A1 (es) | Pirazolobenzodiazepinas disustituidas | |
| SV2006002098A (es) | Compuestos de morfolina sustituida para el tratamiento de trastornos del sistema nervioso central ref. pc32250a | |
| AR047529A1 (es) | Compuestos de quinolina sustituidos | |
| CY1111733T1 (el) | Παραγωγα 2-(1η-ινδολυλοσουλφανυλ)-βενζυλαμινης ως ssri | |
| DOP2009000291A (es) | Compuestos de quinolina adecuados para el tratamiento de trastornos que responden a la modulacion del receptor de serotonina 5-ht6 | |
| PA8779101A1 (es) | "compuestos tricíclicos como inhibidores de metaloproteinasas matriciales" | |
| ATE384039T1 (de) | Indanderivate als muscarinrezeptoragonisten | |
| CL2008001671A1 (es) | Compuestos derivados de piperidina/piperazina inhibidores de dgat1, composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades metabolicas especialmente diabetes. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |